drugset / Trial / NCT04920331
Study of Intravenous Erenumab in Patients With Status Migrainosus
NaSingle-groupOpen-labelTreatment
Summary
The investigators will evaluate the efficacy for use of intravenous erenumab 140mg for treatment of status migrainosus in an open-label, pilot study.
Timeline
- Start
- 2021-09-07
- Primary completion
- 2022-02-04
- Completion
- 2022-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erenumab | Monoclonal antibody | 140 mg | Intravenous |